Proud to share our @ash.hematology.org @bloodjournals.hematology.org, led by my trainee Dr. @vpizzuti.bsky.social @cuinternalmed.bsky.social. Longitudinal PROs and QoL trajectories over 2 years after CAR T-cell therapy. #lymsm #mmsm🧵 doi.org/10.1016/j.bn...

Show Post

Self-promotion. news.cuanschutz.edu/cancer-cente...

Show Post

Jamie Studts, PhD, leads with earnestness, collaboration, and deep respect for community voice — encouraging researchers to pursue what they’re passionate about while grounding science in real-world impact. Full interview: youtu.be/RihtmBmGlIk

Show Post

CAR T-cell therapy has revolutionized treatment of stubborn cancers. Now, a groundbreaking study from @cucancercenter.bsky.social researchers addresses “a huge unanswered gap” in how CAR T-cell therapy impacts patients over two years. @cuanschutz.bsky.social @majorajay.bsky.social #cucityofhealth

Show Post

In a new study, Ajay Major (@majorajay.bsky.social), MD, MBA, and Vincenzo Pizzuti, MD, MS, have tracked a group of blood cancer patients using multiple surveys over the course of two years to see how CAR T-cell therapy impacts their health-related quality of life: https://bit.ly/3UzIYxF

Show Post